OncoCyte Gestion

Gestion contrôle des critères 2/4

Le PDG OncoCyte est Josh Riggs, nommé en Dec2022, a un mandat de 1.92 ans. La rémunération annuelle totale est $ 724.91K, composée du salaire de 46.9% et des bonus 53.1%, y compris les actions et options de la société. détient directement 0.021% des actions de la société, d'une valeur de $ 9.50K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.7 ans et 3.8 ans.

Informations clés

Josh Riggs

Directeur général

US$724.9k

Rémunération totale

Pourcentage du salaire du PDG	46.9%
Durée du mandat du directeur général	1.9yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	1.7yrs
Durée moyenne du mandat des membres du conseil d'administration	3.8yrs

Mises à jour récentes de la gestion

Recent updates

Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oct 28

Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test

Aug 30

Analyse de la rémunération des PDG

Comment la rémunération de Josh Riggs a-t-elle évolué par rapport aux bénéfices de OncoCyte?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$44m
Jun 30 2024	n/a	n/a	-US$37m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$725k	US$340k	-US$26m
Sep 30 2023	n/a	n/a	-US$22m
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$514k	US$242k	-US$19m

Rémunération vs marché: La rémunération totale de Josh ($USD 724.91K ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 647.72K ).

Rémunération et revenus: La rémunération de Josh a augmenté alors que l'entreprise n'est pas rentable.

PDG

Josh Riggs (41 yo)

1.9yrs

Titularisation

US$724,910

Compensation

Mr. Joshua Riggs, also known as Josh, serves as Director of OncoCyte Corporation since February 28, 2023, serves as its Chief Executive Officer & President since February 24, 2023. He served as Interim Chi...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Joshua Riggs	President	1.9yrs	US$724.91k	0.021% $ 9.5k
James Liu	Senior Director	2.2yrs	US$304.51k	0% $ 0
Ekkehard Schutz	Chief Science Officer	1.8yrs	US$575.17k	0.030% $ 13.8k
Andrea James	Chief Financial Officer	less than a year	pas de données	0.20% $ 91.2k
Yuh-Min Chiang	Chief Technology Officer	1.5yrs	pas de données	pas de données
Peter Hong	VP, General Counsel & Secretary	less than a year	pas de données	pas de données
Sandra O'Donald	Senior Vice President of Business Operations	1.3yrs	pas de données	pas de données
Michael West	Scientific Advisor	9.1yrs	US$328.84k	pas de données

1.7yrs

Durée moyenne de l'emploi

41yo

Âge moyen

Gestion expérimentée: L'équipe de direction de OCX n'est pas considérée comme expérimentée (ancienneté moyenne 1.7 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Joshua Riggs	President	1.8yrs	US$724.91k	0.021% $ 9.5k
Louis Silverman	Lead Independent Director	2yrs	US$97.70k	0.0093% $ 4.2k
Andrew Arno	Independent Chairman	9.4yrs	US$112.54k	0.50% $ 229.4k
Daniel Hayes	Member of Scientific & Medical Advisory Board	3.8yrs	pas de données	pas de données
David R. Gandara	Member of Scientific & Medical Advisory Board	no data	pas de données	pas de données
Robert Ferris	Member of Scientific & Medical Advisory Board	no data	pas de données	pas de données
John Kirkwood	Member of Scientific & Medical Advisory Board	3.8yrs	pas de données	pas de données
Andrew Last	Independent Director	8.9yrs	US$92.86k	0.027% $ 12.2k
Fred Hirsch	Member of Scientific & Medical Advisory Board	3.8yrs	pas de données	pas de données
Heinz-Josef Lenz	Member of Scientific & Medical Advisory Board	3.8yrs	pas de données	pas de données
Ignacio Wistuba	Member of Scientific & Medical Advisory Board	3.8yrs	pas de données	pas de données

3.8yrs

Durée moyenne de l'emploi

64.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de OCX sont considérés comme expérimentés (ancienneté moyenne 3.8 ans).

OncoCyte Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

OncoCyte Corporation Appoints Andrea James as Chief Financial Officer

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

Oncocyte Corporation Announces Executive Changes

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Corporation Announces Executive Changes

Recent updates

OncoCyte Corporation to Report Q3, 2024 Results on Nov 12, 2024

Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $0.316184 million.

OncoCyte Corporation has filed a Follow-on Equity Offering in the amount of $7.5 million.

OncoCyte Corporation to Report Q2, 2024 Results on Aug 08, 2024

Oncocyte Announces Notice of Prior Non-Compliance and Subsequent Compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)

OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation Appoints Andrea James as Chief Financial Officer

Oncocyte Corporation Announces Promising Results in A Phase 2 Clinical Trial

Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results

OncoCyte Corporation to Report Q1, 2024 Results on May 15, 2024

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

OncoCyte Corporation announced that it has received $15.8 million in funding

Broadwood Capital, Inc. Engages with OncoCyte Corporation

OncoCyte Corporation announced that it expects to receive $15.8 million in funding

OncoCyte Corporation announced delayed annual 10-K filing

Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays

OncoCyte Corporation to Report Q3, 2023 Results on Nov 09, 2023

Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage

Oncocyte Corporation Announces Executive Changes

OncoCyte Regains Compliance with Nasdaq Listing Requirements

OncoCyte Corporation to Report Q2, 2023 Results on Aug 10, 2023

Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients

Oncocyte Announces 1-For-20 Reverse Stock Split to Regain Compliance with Minimum Bid Price Requirement

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Oncocyte Applies to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

OncoCyte Corporation Announces Reduction of Workforce

OncoCyte Corporation Announces Executive Changes

Melinda Griffith Notifies Oncocyte Corporation F Her Resignation from the Board, Effective January 1, 2023

Consensus forecasts updated

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$2.13

OncoCyte Corporation to Report Q3, 2022 Results on Nov 10, 2022

Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oncocyte Corporation Appoints James Liu as Controller and Principal Accounting Officer

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on Determarx to CMS

Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer

Independent Chairman recently bought US$144k worth of stock

OncoCyte Corporation Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

OncoCyte Corporation Appoints Anish John as Chief Financial Officer

OncoCyte Corporation Announces the Appointment of John Peter Gutfreund as Independent Member of its Board of Directors

OncoCyte Corporation to Report Q2, 2022 Results on Aug 10, 2022

OncoCyte Corporation Announces Resignation of Li Yu as Controller and Principal Accounting Officer

OncoCyte Corporation(NasdaqGM:OCX) dropped from Russell 2000 Dynamic Index

OncoCyte Corporation, Annual General Meeting, Jul 15, 2022

Consensus forecasts updated

Price target decreased to US$3.61

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oncocyte Corporation Completes Validation of TheraSure™ Transplant Monitor Test

Revisiting OncoCyte Corp.

High number of new directors

Price target decreased to US$5.02

Broadwood Capital Engages in Discussions with OncoCyte Corporation

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $35.000001 million.

Consensus revenue estimates fall by 28%

Full year 2021 earnings: EPS exceeds analyst expectations

OncoCyte Corporation to Report Q4, 2021 Results on Mar 10, 2022

Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?

OncoCyte Corporation Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer

Price target decreased to US$7.80

Price target decreased to US$8.00

Oncocyte Corporation Announces Results from DetermaIO™ Test

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2020)